Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?

The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kattan, Joseph, Kattan, Clarisse, Assi, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161588/
https://www.ncbi.nlm.nih.gov/pubmed/32290754
http://dx.doi.org/10.2217/imt-2020-0077
_version_ 1783522978702557184
author Kattan, Joseph
Kattan, Clarisse
Assi, Tarek
author_facet Kattan, Joseph
Kattan, Clarisse
Assi, Tarek
author_sort Kattan, Joseph
collection PubMed
description The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents.
format Online
Article
Text
id pubmed-7161588
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-71615882020-04-16 Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection? Kattan, Joseph Kattan, Clarisse Assi, Tarek Immunotherapy Editorial The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) has been declared a pandemic by the WHO that claimed the lives of thousands of people within a few months. Cancer patients represent a vulnerable population due to the acquired immunodeficiency associated with anti-cancer therapy. Immune checkpoint inhibitors have largely impacted the prognosis of a multitude of malignancies with significant improvement in survival outcomes and a different, tolerable toxicity profile. In this paper, we assess the safety of ICI administration in cancer patients during the coronavirus pandemic in order to guide the usage of these highly efficacious agents. Future Medicine Ltd 2020-04-15 2020-04 /pmc/articles/PMC7161588/ /pubmed/32290754 http://dx.doi.org/10.2217/imt-2020-0077 Text en © 2020 Future Medicine Ltd This work is licensed under the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/)
spellingShingle Editorial
Kattan, Joseph
Kattan, Clarisse
Assi, Tarek
Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?
title Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?
title_full Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?
title_fullStr Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?
title_full_unstemmed Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?
title_short Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?
title_sort do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to covid-19 infection?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161588/
https://www.ncbi.nlm.nih.gov/pubmed/32290754
http://dx.doi.org/10.2217/imt-2020-0077
work_keys_str_mv AT kattanjoseph docheckpointinhibitorscompromisethecancerpatientsimmunityandincreasethevulnerabilitytocovid19infection
AT kattanclarisse docheckpointinhibitorscompromisethecancerpatientsimmunityandincreasethevulnerabilitytocovid19infection
AT assitarek docheckpointinhibitorscompromisethecancerpatientsimmunityandincreasethevulnerabilitytocovid19infection

Ejemplares similares